Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target ⊖
Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.